Terms: = Lymphoma AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
1047 results:
1. Expression and prognostic significance of the PD-1/pd-l1 pathway in AIDS-related non-Hodgkin lymphoma.
Zhao H; Cai S; Xiao Y; Xia M; Chen H; Xie Z; Tang X; He H; Peng J; Chen J
Cancer Med; 2024 Apr; 13(7):e7195. PubMed ID: 38613207
[TBL] [Abstract] [Full Text] [Related]
2. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells.
Camoglio C; Balla J; Fadda P; Dedoni S
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
[TBL] [Abstract] [Full Text] [Related]
3. Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.
Al Taher RS; Abbas MA; Halahleh K; Sughayer MA
Technol Cancer Res Treat; 2024; 23():15330338241242635. PubMed ID: 38562094
[No Abstract] [Full Text] [Related]
4. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell lymphoma.
Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
[TBL] [Abstract] [Full Text] [Related]
5. Differential Upregulation of Th1/Th17-Associated Proteins and pd-l1 in Granulomatous Mycosis Fungoides.
Marques-Piubelli ML; Navarrete J; Ledesma DA; Hudgens CW; Lazcano RN; Alani A; Huen A; Duvic M; Nagarajan P; Aung PP; Wistuba II; Curry JL; Miranda RN; Torres-Cabala CA
Cells; 2024 Feb; 13(5):. PubMed ID: 38474383
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma.
Liu F; Tian S; Liu Q; Deng Y; He Q; Shi Q; Chen G; Xu X; Yuan J; Nakamura S; Karube K; Wang Z
Cancer Med; 2024 Feb; 13(4):e6995. PubMed ID: 38457199
[TBL] [Abstract] [Full Text] [Related]
7. Association of pd-l1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract] [Full Text] [Related]
8. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J; Cheng S; Gao X; Yu SH; Dai YT; Huang XY; Zhong HJ; Wang CF; Yi HM; Zhang H; Cao WG; Li R; Tang W; Zhao Y; Xu PP; Wang L; Zhao WL
Signal Transduct Target Ther; 2024 Mar; 9(1):62. PubMed ID: 38448403
[TBL] [Abstract] [Full Text] [Related]
9. Correlation between PD-1 and spd-l1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
[TBL] [Abstract] [Full Text] [Related]
10. The association of genomic alterations with pd-l1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
[TBL] [Abstract] [Full Text] [Related]
11. pd-l1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
[TBL] [Abstract] [Full Text] [Related]
12. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
[TBL] [Abstract] [Full Text] [Related]
13. The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
Slak TC; Miceska S; Gasljevic G; Boltezar L; Kloboves-Prevodnik V
Radiol Oncol; 2024 Mar; 58(1):99-109. PubMed ID: 38378036
[TBL] [Abstract] [Full Text] [Related]
14. Epstein-Barr Virus Promotes Tumorigenicity and Worsens Hodgkin lymphoma Prognosis by Activating JAK/STAT and NF-κB Signaling Pathways.
Alabiad MA; Said WMM; Saad RHF; Balata R; Mahmoud AA; Metwally EA; Shalaby AM; Samy W; Yehia AM; Yahia AIO; Alorini M; Abdelrahman DI
Iran J Med Sci; 2024 Feb; 49(2):88-100. PubMed ID: 38356485
[TBL] [Abstract] [Full Text] [Related]
15. Molecular analysis of endobronchial ultrasound needle aspirates in patients with non-small cell lung cancer: Results from the SCOPE database.
Vakil E; Dumoulin E; Stollery D; Gillson AM; MacEachern P; Dhaliwal I; Mitchell M; Li P; Schieman C; Romatowski N; Chee AC; Tyan CC; Fortin M; Hergott CA; Tremblay A
Cytopathology; 2024 May; 35(3):378-382. PubMed ID: 38349229
[TBL] [Abstract] [Full Text] [Related]
16. BCLAF1 binds SPOP to stabilize pd-l1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract] [Full Text] [Related]
17. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract] [Full Text] [Related]
18. Frequent expression of pd-l1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract] [Full Text] [Related]
19. Presence of Epstein-Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma.
Mangiaterra T; Alonso-Alonso R; Rabinovich A; De Dios Soler M; Galluzzo L; Soria M; Colli S; De Matteo E; Rodriguez Pinilla SM; Chabay P
Cancer Immunol Immunother; 2024 Jan; 73(2):29. PubMed ID: 38280007
[TBL] [Abstract] [Full Text] [Related]
20. Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.
Lin YT; Wang C; He XY; Yao QM; Chen J
Front Immunol; 2023; 14():1345942. PubMed ID: 38274823
[TBL] [Abstract] [Full Text] [Related]
[Next]